Treace Medical Concepts, Inc.

NASDAQ:TMCI

Medical - Devices

Healthcare
$4.53 +1.87%

+$0.08 today

Market cap
$296.98M
Beta
1.41
P/E (TTM)
-4.3
EPS (TTM)
-$0.95
52W Low $1.17High $7.78

Volume 0.18M

Average 0.73M

TMCI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Treace Medical Concepts, Inc.NASDAQ: TMCI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $17.96M (cash outflow) rose 12.8% year over year, behind the +15.2% change in trailing-twelve-month net income. Sequentially, it rose 91.2% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.

Context

  • Net income amounted to 27.7% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$51.38M (-12.9%) for the fiscal year ending Dec 2026, a slowdown from the +5.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.96M+91.2% QoQ
Last fiscal yearDec 2025
-$59M+5.8% YoY
LTMMar 2026
-$61.04M+15.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%+12.1%-0.7 pp
1 year+5.8%-12.9%-18.8 pp
3-year CAGR+11.3%-10.3%-21.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(59M) USD
Year-over-year change
-5.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TMCI compares with its peers on the latest reported figures

  • TMCI's LTM Mar 2026 net income of $61.04M is the 2nd largest of the 8 companies compared; the peer median is $39.68M.
  • Its year-over-year change of +15.2% is the 5th highest of 8, against a peer median of +35.0%.
  • Net income amounts to 29.4% of revenue for TMCI, versus a peer median of 16.3%.
TMCI Competitors Peer median
Net Income for TMCI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LABStandard BioTools Inc.LTM Mar 2026$78.21M +158.9%-26.7%90.7%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$61.04M +15.2%+11.3%29.4%
CBLLCeriBell, Inc.LTM Mar 2026$60.37M +35.0%+12.9%63.5%
RXSTRxSight, Inc.LTM Mar 2026$46.64M +75.7%-16.4%36.6%
EOLSEvolus, Inc.LTM Mar 2026$43.42M -22.7%-11.5%14.4%
KIDSOrthoPediatrics Corp.LTM Mar 2026$39.68M -2.5%—16.3%
BVSBioventus Inc.LTM Mar 2026$33.69M +201.9%—5.8%
TOIThe Oncology Institute, Inc.LTM Mar 2026$4.27M -93.1%—0.8%
Peer median (excluding TMCI) $39.68M+35.0%-14.0%16.3%

Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Depreciation & Amortization685K2.13M5.35M8.42M10.5M
Deferred Income Tax419K0000
Stock-Based Compensation3.41M8.11M17.35M30.6M33.82M
Change in Working Capital(1.33M)(5.81M)(9.74M)(25.43M)(8.58M)
Accounts Receivables(4.23M)(11.04M)(9.3M)(5.69M)(2.09M)
Inventory(3.09M)(8.77M)(9.85M)(10.01M)3.22M
Accounts Payables1.79M4.61M3.17M(1.31M)(3.8M)
Other Working Capital4.19M9.39M6.24M(8.42M)(5.92M)
Other Non-Cash Items176K7.73M1.99M4.99M7.29M
Operating Cash Flow(17.19M)(30.65M)(34.58M)(37.17M)(15.97M)
Capital Expenditures(2.71M)(14.84M)(11.46M)(11.59M)(13.52M)
Acquisitions (Net)061.68M(20M)00
Purchases of Investments0(63.41M)(169.87M)(71.58M)(40.57M)
Sales of Investments01.73M120.02M118.55M67.34M
Other Investing Activities0(61.68M)000
Investing Cash Flow(2.71M)(76.52M)(81.3M)35.38M13.25M
Debt Repayment(1.79M)19.61M002.43M
Common Stock Issued109.44M2.19M109.4M428K546K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(989K)(13K)(268K)(902K)
Financing Cash Flow107.65M20.81M109.38M160K2.08M
Effect of Forex Changes00000
Net Change in Cash87.75M(86.36M)(6.49M)(1.63M)(642K)
Free Cash Flow(19.9M)(45.49M)(46.03M)(48.76M)(29.49M)

Treace Medical Concepts, Inc.

NASDAQ:TMCI

Intrinsic Alpha fair value

Locked

Current Price

$4.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.